Purchase of SIRTURO (Bedaquiline) 100mg Tablets

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH), Clinical Center (CC), the world’s foremost research hospital, intends to award a Fixed Price Purchase Order for the drug SIRTURO ® ; Bedaquiline, 100mg Tablets, to Cardinal Health 108, Doing Business As Metro Medical Supply, 200 Cumberland Bend, Nashville, TN, 37228-1804, the only distributor authorized by the manufacturer of SIRTURO®, Janssen Pharmaceuticals.  SIRTURO® is required for patient care by the NIH CC Pharmacy Department as necessary to fulfill the current need.  The Government intends to include a base period of 12 months and four (4) twelve month Option Periods, options for additional quantities, as well as economic price adjustment clauses. Purchase of SIRTURO will provide relief for multiple patients enrolled in research at the NIH Clinical Center.

This acquisition is being conducted using policies unique to the acquisition of commercial items prescribed in FAR Part 12 in conjunction with the policies and procedures for the competition requirements in FAR Part 6.  Interested parties may identify their interest and capabilities in response to this posting.  The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Lisa Schaupp, Contract Specialist, Lisa.Schaupp@nih.gov,  by the due date and time marked in this notice.